Why Neurogene Inc.’s (NGNE) Stock Is Down 6.93%
As of Wednesday, September 23, Neurogene Inc.’s NGNE share price has dipped by 6.93%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Commentary & Analysis
Why Neurogene Inc.’s (NGNE) Stock Is Up 6.76%
As of Wednesday, August 19, Neurogene Inc.’s NGNE share price has surged by 6.76%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Neurogene Inc.’s (NGNE) Stock Is Down 6.07%
As of Tuesday, August 11, Neurogene Inc.’s NGNE share price has dipped by 6.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Neurogene Inc.’s (NGNE) Stock Is Down 5.43%
As of Friday, July 10, Neurogene Inc.’s NGNE share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Michael Rose
Why Neurogene Inc.’s (NGNE) Stock Is Up 5.95%
As of Thursday, July 09, Neurogene Inc.’s NGNE share price has surged by 5.95%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | NGNE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $513.3 | $250.1 | 38% |
|
| Shares Out (Mil) | 22.6 | 54.0 | 32% |
|
| Institutional Ownership | 88.4% | 93.1% | 56% |
|
| Float (Mil) | 11.3 | 41.4 | 21% |
|
| Beta | 1.95 | 0.95 | 91% |
|
| Avg Daily Volume (000s) | 350 | 661 | 52% |
|
| Price Change (52-week) |
42.7% | 49.5% | 81% |
|
| Growth | NGNE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 4 | |
| Current EPS | ($1.420) | ($5.656) | ($5.178) | |
| Month Ago EPS | ($1.420) | ($5.656) | ($5.178) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 2 | |
| Three Months Ago EPS | ($1.275) | ($5.313) | ($5.458) | |
| Year/Year Chg | (7.1%) | 33.5% | (34.3%) | |
| Financials | NGNE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($111) | ($44) | 10% |
|
| EPS (TTM) | ($5.044) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($87) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $54 | $2 | 71% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | $523 | $175 | 34% |
|
| Valuation | NGNE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.87 | 2.36 | 50% |
|
| P/E | na | 18.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NGNE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (41.0%) | (47.6%) | 13% |
|
| ROE | (45.3%) | (54.9%) | 16% |
|
| Liabilities to Assets | 11.1% | 29.3% | 7% |
|
| F-Score | 2 | 3 | 7% |
|
Neurogene Inc. did not pass any screens on 10/2/2026.
